SRCM
PBAXU

Sage Rock Capital Management’s Phoenix Biotech Acquisition Corp. Unit PBAXU Stock Holding History

Sage Rock Capital Management’s Portfolio PBAXU Stock Details PBAXU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-184,000
Closed -$1.85M – 328
2022
Q1 		$1.85M Hold
184,000
– – 0.33% 117
2021
Q4 		$1.86M Buy
+184,000
New +$1.86M 0.28% 129

Other funds holding PBAXU

SCM
Shaolin Capital Management Miami, Florida $2.1B AUM 64.05% 1-Year Est. Return
CCA
Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
WC
Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
SIA
Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
DCM
Difesa Capital Management New York $38.1M AUM 39.86% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return

Sage Rock Capital Management's PBAXU Position: Q2 2022 in Review

Sage Rock Capital Management sold out of Phoenix Biotech Acquisition Corp. Unit (PBAXU) in Q2 2022, closing a stake of 184,000 shares — an estimated $1.85M sold.

Sage Rock Capital Management first reported a position in PBAXU in Q4 2021 and held it in 2 quarters. The position peaked at $1.86M in Q4 2021. 26 funds tracked by Wall St. Rank hold PBAXU as of Q2 2022.

  • Sage Rock Capital Management reported no remaining Phoenix Biotech Acquisition Corp. Unit position as of Q2 2022 after selling out during the quarter.
  • Sage Rock Capital Management sold 184,000 Phoenix Biotech Acquisition Corp. Unit shares in Q2 2022, an estimated $1.85M.
  • Sage Rock Capital Management first reported a position in Phoenix Biotech Acquisition Corp. Unit in Q4 2021 and held it in 2 quarters.
  • Sage Rock Capital Management's Phoenix Biotech Acquisition Corp. Unit position peaked at $1.86M in Q4 2021.
  • 26 funds tracked by Wall St. Rank held Phoenix Biotech Acquisition Corp. Unit as of Q2 2022.

Based on Sage Rock Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.